| Name | Title | Contact Details |
|---|
ValueOptions Inc., the nation's largest independent behavioral health care and wellness company, specializes in management for all behavioral health issues, and mental health and chemical dependency diagnoses.
Actavis is a unique global specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world. The Company has global headquarters in Dublin, Ireland. Actavis markets a broad portfolio of branded pharmaceuticals and is focused on developing new medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapeutic categories. Actavis is also the world`s third-largest generics prescription drug manufacturer, marketing generic, branded generic, and Over-the-Counter (OTC) products in more than 60 countries. Actavis Global Operations has more than 35 manufacturing and distribution facilities around the world and includes Anda, Inc., a U.S. pharmaceutical product distributor.
Aeryon Labs Inc is a Waterloo, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ and TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients` lives while focusing on creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez`s Global Headquarters is in Ontario, Canada, the US Headquarters is planned to be in Princeton, NJ and the Irish Headquarters is in Dublin, Ireland.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.